Investigation reveals access issues to disease modifying therapies in young adults with multiple sclerosis, highlighting significant healthcare gaps.
Understand the demographic characteristics and access to disease modifying therapies (DMTs) in young adults living with multiple sclerosis
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: